Cite
HARVARD Citation
Kumari, R. et al. (2018). Complete Response to Afatinib in Lung Adenocarcinoma of Epidermal Growth Factor Receptor Exon-19 Deletion Mutation and Disease Recurrence on Drug Discontinuation. Journal of pharmacology and pharmacotherapeutics. 9 (4), pp. 191-194. [Online].